News Releases

Rutgers Cancer Institute of New Jersey and RWJBarnabas Health Announce Three Late-Breaking Presentations at the 2023 ASCO Annual Meeting

Physician-scientists will present expansive new cancer research, including 33 accepted abstracts

NEW BRUNSWICK, N.J., May 25, 2023 /PRNewswire/ -- Rutgers Cancer Institute of New Jersey and RWJBarnabas Health today announced that data from SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL), and two abstracts from the neoadjuvant I-SPY 2 trial evaluating oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer, have been selected as late-breaking presentations at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held both in person in Chicago and online from June 2-6.

"We are thrilled to have physician-scientists from our health system participate in two innovative clinical trials selected for three late-breaking presentations at this year's ASCO annual meeting, reinforcing our commitment to push the boundaries of science, provide patients with cutting-edge treatment options, and transform the way cancer is treated," said Steven K. Libutti, MD, FACS, Director, Rutgers Cancer Institute of New Jersey and Senior Vice President, Oncology Services, RWJBarnabas Health. "As New Jersey's only NCI-Designated Comprehensive Cancer Center, we strive to offer our patients comprehensive cancer care, including access to novel therapeutic advances and game-changing clinical trials that have the potential to save, extend and improve the quality of patients' lives, and reshape the future of cancer management."

A total of 33 presentations and 9 publications have been accepted, highlighting research advances in several types of cancer, including lymphoma, pediatric, colorectal and breast cancer.

Highlights of additional accepted abstracts include the following:

Initial findings of the phase II study of biweekly TAS-102, irinotecan and bevacizumab in pre-treated metastatic colorectal cancer (mCRC), found that TAS-102 with irinotecan plus bevacizumab is an effective second-line therapy for patients with mCRC.
Findings from a cross-sectional, retrospective analysis that aimed to determine the association of receipt of treatment summaries, follow-up care instructions (including where to obtain "routine cancer check-ups"), and type of doctor providing survivorship care on breast cancer screening (BCS) and cervical cancer screening (CCS) in female cancer survivors. The analysis demonstrated that follow-up instructions, which are part of the survivorship plan, have the greatest association with BCS and CCS among cancer survivors, but despite this, about 25% of BCS and CCS-eligible cancer survivors did not receive them.
Results from a phase Ib/II clinical trial evaluating the preliminary safety and efficacy of tinengotinib tablets as monotherapy and combination therapy in advanced solid tumors, which demonstrated that tinengotinib monotherapy was well-tolerated and the pharmacokinetics results may support dose recommendation for subsequent trials. Additionally, researchers observed encouraging anticancer activity of tinengotinib monotherapy in patients with heavily pre-treated solid tumors, including PC, HR+/HER2- BC, TNBC and CCA.

The full list of presentations at the 2023 ASCO Annual Meeting follows:

Oral Presentations
Abstract No.	Title	Presentation Date/Time	Location
Abstract 8006	LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma.	Saturday, June 3, 2023, 3:15 p.m. CDT	Hall D2 & Live Stream
Abstract 9501	Significant durable response with fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1) in advanced melanoma: Post adjuvant PD-1 analysis.	Monday, June 5, 2023, 3:00 p.m. CDT	Hall D1 & Live Stream
Abstract 1004	A phase 2 study of HER3-DXd in patients (pts) with metastatic breast cancer (MBC).	Monday, June 5, 2023, 12:42 p.m. CDT	Hall B1 & Live Stream
Abstract 10008	Phase 2 study of larotrectinib in children with newly diagnosed infantile fibrosarcoma (IFS): Children's Oncology Group (COG) ADVL1823 cohort A.	Sunday, June 4, 2023, 12:09 p.m. CDT	S100a & Live Stream
Poster Presentations
Abstract No.	Title	Presentation Date/Time	Location
Abstract LBA612	Oral paclitaxel and dostarlimab with or without trastuzumab in early- stage, high-risk breast cancer: Results from the neoadjuvant I SPY 2 TRIAL.	Sunday, June 4, 2023, 8:00 – 11:00 a.m. CDT	Hall A & On Demand
Abstract TPS3625	Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).	Monday, June 5, 2023, 8:00 – 11:00 a.m. CDT	Hall A & On Demand
Abstract TPS5103	SWOG S1823/CCTG GCC1: Translational observational investigational study of the liquid biomarker microRNA 371a-3p in newly diagnosed germ cell tumours—Real-world trial design, rapid accrual, and robust secondary use of data opportunities.	Saturday, June 3, 2023, 8:00 – 11:00 a.m. CDT	Hall A & On Demand
Abstract TPS5109	HB-300, a novel arenavirus-based cancer immunotherapy in patients with metastatic castration-resistant prostate cancer.	Saturday, June 3, 2023, 8:00 – 11:00 a.m. CDT	Hall A & On Demand
Abstract TPS5110	A phase 1/2 study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer with bone metastases (COMRADE): A trial in progress.	Saturday, June 3, 2023, 8:00 – 11:00 a.m. CDT	Hall A & On Demand
Abstract TPS9594	A phase 2/3 trial in progress on tebentafusp as monotherapy and in combination with pembrolizumab in HLA-A*02:01+ patients with previously treated advanced non- uveal melanoma (TEBE-AM).	Saturday, June 3, 2023, 1:15 – 4:15 p.m. CDT	Hall A & On Demand
Abstract 532	A multicenter phase II study of vaccines to prevent recurrence in patients with HER-2–positive breast cancer.	Sunday, June 4, 2023, 8:00 – 11:00 a.m. CDT	Hall A & On Demand
Abstract 2561	Clinical outcomes of immune checkpoint inhibitor treatment in patients with classic cold tumors identified to have a high tumor mutational burden via ctDNA.	Saturday, June 3, 2023, 8:00 – 11:00 a.m. CDT	Hall A & On Demand
Abstract 3085	Characterization of MCL-1 in patients with colorectal cancer (CRC): Expression, molecular profiles, and outcomes.	Monday, June 5, 2023, 8:00 – 11:00 a.m. CDT	Hall A & On Demand
Abstract 3531	Chemotherapeutic sensitivity in colorectal cancer expressing low RNA of wild type homologous recombination genes.	Monday, June 5, 2023, 8:00 – 11:00 a.m. CDT	Hall A & On Demand
Abstract 3590	Phase II study of biweekly TAS- 102, irinotecan and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO).	Monday, June 5, 2023, 8:00 – 11:00 a.m. CDT	Hall A & On Demand
Abstract 3622	Molecular profiling and characterization of the tumor immune microenvironment (TME) in appendiceal carcinoma (AC).	Monday, June 5, 2023, 8:00 – 11:00 a.m. CDT	Hall A & On Demand
Abstract 4108	Comprehensive profiling of clock genes expression in hepatocellular carcinoma (HCC).	Monday, June 5, 2023, 8:00 – 11:00 a.m. CDT	Hall A & On Demand
Abstract 4144	Correlation of comprehensive molecular mapping of pancreatic ductal adenocarcinoma with XPO1 mRNA expression levels to potential clinical targets.	Monday, June 5, 2023, 8:00 – 11:00 a.m. CDT	Hall A & On Demand
Abstract 4145	Clinical genomic implications of transcriptional subtypes in pancreatic cancer.	Monday, June 5, 2023, 8:00 – 11:00 a.m. CDT	Hall A & On Demand
Abstract 4150	KRAS G12C-mutated pancreatic cancer: Clinical outcomes based on chemotherapeutic regimen.	Monday, June 5, 2023, 8:00 – 11:00 a.m. CDT	Hall A & On Demand
Abstract 4151	Molecular and clinical correlates of DSCR1 expression in pancreatic cancer (PDAC).	Monday, June 5, 2023, 8:00 – 11:00 a.m. CDT	Hall A & On Demand
Abstract 4167	The five periampullary cancers: Not just different siblings but different families—An international multicenter cohort study.	Monday, June 5, 2023, 8:00 – 11:00 a.m. CDT	Hall A & On Demand
Abstract 9548	A phase 1 study of fianlimab (anti- LAG-3) in combination with cemiplimab (anti-PD-1) in patients with advanced melanoma: Poor- prognosis subgroup analysis.	Saturday, June 3, 2023, 1:15 – 4:15 p.m. CDT	Hall A & On Demand
Abstract 10628	Learned lessons from a US-wide outreach program to broaden enrollment to the PROMISE Registry, a prostate cancer genetic registry.	Saturday, June 3, 2023, 1:15 – 4:15 p.m. CDT	Hall A & On Demand
Abstract 11018	Characterizing imposter syndrome among oncologists on social media.	Sunday, June 4, 2023, 8:00 – 11:00 a.m. CDT	Hall A & On Demand
Abstract 12075	Survivorship care and breast and cervical cancer screening.	Monday, June 5, 2023, 1:15 – 4:15 p.m. CDT	Hall A & On Demand
Poster Discussion Session
Abstract 2519	A phase I/II trial investigating safety and efficacy of autologous TAC01- HER2 in relapsed or refractory solid tumors.	Saturday, June 3, 2023, 3:00 – 4:30 p.m. CDT	S100bc & On Demand
Abstract 3019	Preliminary safety and efficacy of tinengotinib tablets as monotherapy and combination therapy in advanced solid tumors: A phase Ib/II clinical trial.	Saturday, June 3, 2023, 2:11 p.m. CDT	S100bc & On Demand
Abstract 4020	Not all treated KRAS-mutant pancreatic adenocarcinomas are equal: KRAS G12D and survival outcome.	Monday, June 5, 2023, 11:30 – 1:00 p.m. CDT	Hall D2 & Live Stream
Abstract 7515	Response-adapted therapy (tx) with nivolumab plus brentuximab vedotin (nivo + BV) without autologous hematopoietic cell transplantation (auto-HCT) in children, adolescents, and young adults (CAYA) with low- risk relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL): CheckMate 744.	Monday, June 5, 2023, 1:49 p.m. CDT	E450 & On Demand
Abstract Discussion 4	Aging in Survivors of Pediatric Cancer	Monday, June 5, 2023, 5:36 p.m. CDT	S504 & On Demand
Abstract LBA520	Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL.	Sunday, June 4, 2023, 5:04 p.m. CDT	Hall B1 & Live Stream
Plenary Session
Abstract LBA4	SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin (BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL).	Sunday, June 4, 2023, 2:53 p.m. CDT	Hall B1 & Live Stream
Publication Only
Session title	Presentation title	Presentation Date/Time	Location
Abstract e16073	Preoperative pembrolizumab for MSI high, EBV positive or PD-L1 positive locally advanced gastric cancer followed by surgery and adjuvant chemoradiation with pembrolizumab: Interim results of a phase 2 multi-center trial.	N/A	N/A
Abstract e18723	Assessment of how differences in efficacy and toxicity change healthcare professionals' views on presentation of treatment options.	N/A	N/A
Abstract e15087	Safety and feasibility of the addition of a radiosensitizing methionine- restricted diet to radiation therapy.	N/A	N/A
Abstract e17618	Comparing sentinel lymphadenectomy and complete lymphadenectomy among obese patients (BMI >30) undergoing minimally invasive hysterectomy for early-stage endometrial cancer: An ACS-NSQIP database study.	N/A	N/A
Abstract e18605	Immediate inpatient toxicities associated with CAR T-cell therapy: Real world data from a national inpatient sample.	N/A	N/A
Abstract e24088	Barriers to offering female fertility preservation to pediatric and young adult oncology patients: A national survey of pediatric hematology oncology providers in the United States and Canada.	N/A	N/A
Abstract e12523	ctDNA detection before and during systemic therapy for inflammatory breast cancer.	N/A	N/A
Abstract e16079	Outcomes of Helicobacter pylori (HP) infection in esophageal cancer (EC): A 5-year nationwide analysis.	N/A	N/A
Abstract e19015	Pevonedistat plus belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome: A phase I multicenter study.	N/A	N/A

About Rutgers Cancer Institute of New Jersey
As New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute, together with RWJBarnabas Health, offers the most advanced cancer treatment options, including bone marrow transplantation, proton therapy, CAR T-cell therapy and complex surgical procedures. Along with clinical trials and novel therapeutics such as precision medicine and immunotherapy – many of which are not widely available – patients have access to these cutting-edge therapies at Rutgers Cancer Institute of New Jersey in New Brunswick, Rutgers Cancer Institute of New Jersey at University Hospital in Newark, as well as through RWJBarnabas Health facilities. To make a tax-deductible gift to support the Cancer Institute of New Jersey, call 848-932-8013 or visit www.cinj.org/giving.

For journalists – contact:
Krista Didzbalis
Media Relations Assistant
732-507-8307
krista.didzbalis@rutgers.edu

For patient appointments/inquiries – contact:
844-CANCERNJ (844-226-2376)

SOURCE Rutgers Cancer Institute of New Jersey and RWJBarnabas Health